Goldman Sachs’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17M | Sell |
1,421,453
-418,010
| -23% | -$3.47M | ﹤0.01% | 2803 |
|
|
2026
Q1 | $15.4M | Buy |
1,839,463
+54,026
| +3% | +$568K | ﹤0.01% | 2699 |
|
|
2025
Q4 | $25.7M | Sell |
1,785,437
-66,777
| -4% | -$832K | ﹤0.01% | 2137 |
|
|
2025
Q3 | $17.9M | Buy |
1,852,214
+67,708
| +4% | +$599K | ﹤0.01% | 2367 |
|
|
2025
Q2 | $14.7M | Buy |
1,784,506
+1,031,779
| +137% | +$8.64M | ﹤0.01% | 2400 |
|
|
2025
Q1 | $5.38M | Sell |
752,727
-3,511
| -0.5% | -$26.1K | ﹤0.01% | 3277 |
|
|
2024
Q4 | $5.85M | Buy |
756,238
+12,851
| +2% | +$121K | ﹤0.01% | 3297 |
|
|
2024
Q3 | $7.8M | Buy |
743,387
+94,144
| +15% | +$1.15M | ﹤0.01% | 2950 |
|
|
2024
Q2 | $7.6M | Sell |
649,243
-74,362
| -10% | -$1.16M | ﹤0.01% | 2770 |
|
|
2024
Q1 | $15.2M | Buy |
723,605
+387,499
| +115% | +$6.9M | ﹤0.01% | 2075 |
|
|
2023
Q4 | $6.03M | Sell |
336,106
-260,748
| -44% | -$4.59M | ﹤0.01% | 3005 |
|
|
2023
Q3 | $9.82M | Buy |
596,854
+16,875
| +3% | +$306K | ﹤0.01% | 2403 |
|
|
2023
Q2 | $11.6M | Buy |
579,979
+23,268
| +4% | +$448K | ﹤0.01% | 2314 |
|
|
2023
Q1 | $10.5M | Sell |
556,711
-39,757
| -7% | -$880K | ﹤0.01% | 2371 |
|
|
2022
Q4 | $13.5M | Sell |
596,468
-34,695
| -5% | -$784K | ﹤0.01% | 2304 |
|
|
2022
Q3 | $16.7M | Buy |
631,163
+131,038
| +26% | +$3.89M | ﹤0.01% | 2032 |
|
|
2022
Q2 | $12.4M | Buy |
500,125
+381,047
| +320% | +$9.52M | ﹤0.01% | 2302 |
|
|
2022
Q1 | $3.95M | Sell |
119,078
-200,469
| -63% | -$5.57M | ﹤0.01% | 3570 |
|
|
2021
Q4 | $10.4M | Sell |
319,547
-56,795
| -15% | -$1.93M | ﹤0.01% | 2713 |
|
|
2021
Q3 | $15.8M | Sell |
376,342
-6,862
| -2% | -$247K | ﹤0.01% | 2290 |
|
|
2021
Q2 | $14.9M | Buy |
383,204
+22,277
| +6% | +$797K | ﹤0.01% | 2324 |
|
|
2021
Q1 | $12.3M | Sell |
360,927
-368,764
| -51% | -$15.7M | ﹤0.01% | 2372 |
|
|
2020
Q4 | $33.1M | Buy |
729,691
+196,375
| +37% | +$6.86M | 0.01% | 1457 |
|
|
2020
Q3 | $14.7M | Sell |
533,316
-67,438
| -11% | -$2.2M | ﹤0.01% | 1988 |
|
|
2020
Q2 | $22.1M | Sell |
600,754
-37,051
| -6% | -$1.38M | 0.01% | 1599 |
|
|
2020
Q1 | $20.7M | Buy |
637,805
+198,376
| +45% | +$8.27M | 0.01% | 1479 |
|
|
2019
Q4 | $18M | Buy |
439,429
+160,895
| +58% | +$6.36M | ﹤0.01% | 1957 |
|
|
2019
Q3 | $9.92M | Sell |
278,534
-39,815
| -13% | -$1.61M | ﹤0.01% | 2336 |
|
|
2019
Q2 | $16.4M | Sell |
318,349
-9,028
| -3% | -$451K | ﹤0.01% | 2005 |
|
|
2019
Q1 | $18.8M | Sell |
327,377
-12,278
| -4% | -$608K | 0.01% | 1925 |
|
|
2018
Q4 | $14.2M | Sell |
339,655
-81,893
| -19% | -$4.8M | ﹤0.01% | 2073 |
|
|
2018
Q3 | $31.8M | Sell |
421,548
-12,253
| -3% | -$883K | 0.01% | 1562 |
|
|
2018
Q2 | $31.1M | Buy |
433,801
+246,771
| +132% | +$11.8M | 0.01% | 1571 |
|
|
2018
Q1 | $5.58M | Buy |
187,030
+35,308
| +23% | +$1.03M | ﹤0.01% | 2802 |
|
|
2017
Q4 | $5.04M | Sell |
151,722
-12,301
| -7% | -$371K | ﹤0.01% | 3007 |
|
|
2017
Q3 | $5.4M | Buy |
164,023
+50,117
| +44% | +$1.13M | ﹤0.01% | 3069 |
|
|
2017
Q2 | $2.25M | Buy |
113,906
+78,606
| +223% | +$1.52M | ﹤0.01% | 3751 |
|
|
2017
Q1 | $681K | Buy |
35,300
+8,429
| +31% | +$163K | ﹤0.01% | 4727 |
|
|
2016
Q4 | $498K | Buy |
26,871
+11,221
| +72% | +$214K | ﹤0.01% | 5067 |
|
|
2016
Q3 | $219K | Sell |
15,650
-115,252
| -88% | -$1.27M | ﹤0.01% | 5754 |
|
|
2016
Q2 | $1.05M | Buy |
+130,902
| New | +$1.45M | ﹤0.01% | 4145 |
|
Other funds holding RGNX
RG
Goldman Sachs's RGNX Position: Q2 2026 in Review
Goldman Sachs reduced its Regenxbio (RGNX) stake by 23% in Q2 2026, selling an estimated $3.47M and leaving 1,421,453 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2803.
Goldman Sachs first reported a position in RGNX in Q2 2016 and has held it in 41 quarters since. The position peaked at $33.1M in Q4 2020. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- Goldman Sachs held 1,421,453 shares of Regenxbio worth $17M as of Q2 2026.
- Goldman Sachs sold 418,010 Regenxbio shares in Q2 2026, an estimated $3.47M.
- Regenxbio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2803 holding.
- Goldman Sachs first reported a position in Regenxbio in Q2 2016 and has held it in 41 quarters since.
- Goldman Sachs's Regenxbio position peaked at $33.1M in Q4 2020.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.